Acta Chir Orthop Traumatol Cech. 2019; 86(5):320-323 | DOI: 10.55095/achot2019/054
Prediction of the Mortality with Comorbidity - Polypharmacy Score in the Osteoporotic Hip FracturesOriginal papers
- Health Science University, Umraniye Training and Research Hospital, Department of Orthopaedics and Traumatology, Istanbul, Turkey
PURPOSE OF THE STUDY:
Osteoporotic hip fractures commonly associated with comorbid diseases and use of multiple drugs. Polypharmacy status and the comorbidity-polypharmacy score (CPS) are the most common two grading system to predict mortality risk for the trauma patients older than 45 years. The purpose of the study was to determine whether the CPS or polypharmacy can predict the mortality risk in the older patients had a surgery due to an osteoporotic hip fracture.
MATERIAL AND METHODS:
Consecutive patients aged > 65 years had an osteoporotic hip fracture due to a simple trauma were enrolled in the study. Detailed data were collected included comorbid conditions, medications, T-scores and additional fractures. Patients were divided into four groups according to CPS classification and polypharmacy status was indicated in case of using five or more drugs before admission. Overall mortality was assessed using Kaplan-Meier survival testing. Factors influencing 1-year, 2-year and 5-year mortality were evaluated using a multivariate logistic regression model with adjusted odds ratios (AORs) and a threshold significance at p < 0.05.
RESULTS:
A total of 109 patients (65% women) with a mean age 80 ± 8.06 were included in the study. The mean time to death from the surgery was 42.06 ± 34.9 months. The Kaplan-Meier survival curves showed a significant difference in mortality among CPS groups. (Log-Rank test < 0.001). CPS presented a significant prediction in 1-year (AOR: 4.2; p < 0.05) and 2-year mortality (AOR: 2.9; p < 0.05) after adjustment for several covariates (including age, gender, surgical procedure) whereas 5-year mortality did not reveal a significant prediction (p = 0.46) Polypharmacy existence did not independently predict both overall or year-based mortality (p > 0.05).
CONCLUSIONS:
CPS is a better predictor for mortality risk than polypharmacy existence in the first two years in the patients underwent surgery for an osteoporotic hip fracture.
Keywords: osteoporotic hip fracture, mortality, polypharmacy, comorbidity
Published: October 1, 2019 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70:989-995.
Go to original source...
Go to PubMed...
- Evans DC, Cook CH, Christy JM, Murphy CV, Gerlach AT, Eiferman D, Lindsey DE, Whitmill ML, Papadimos TJ, Beery PR, Steinberg SM, Stawicki SP. Comorbidity-polypharmacy scoring facilitates outcome prediction in older trauma patients. J Am Geriatr Soc. 2012;60:1465-1470.
Go to original source...
Go to PubMed...
- Franchi C, Cartabia M, Risso P, Mari D, Tettamanti M, Parabiaghi A, Pasina L, Djignefa DC, Fortino I, Bortolotti A, Merlino L, Nobili A. Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project. Eur J Clin Pharmacol. 2013;69:1477-1483.
Go to original source...
Go to PubMed...
- Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62:2261-2272.
Go to original source...
Go to PubMed...
- Gallagher PF, Barry PJ, Ryan C, Hartigan I, O'Mahony D. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers' Criteria. Age Ageing. 2008;37:96-101.
Go to original source...
Go to PubMed...
- Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG. Polypharmacy cut-off and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989-995.
Go to original source...
Go to PubMed...
- Harstedt M, Rogmark C, Sutton R, Melander O, Fedorowski A. Impact of comorbidity on 6-month hospital readmission and mortality after hip fracture surgery. Injury. 2015;46:713-718.
Go to original source...
Go to PubMed...
- Harstedt M, Rogmark C, Sutton R, Melander O, Fedorowski A. Polypharmacy and adverse outcomes after hip fracture surgery. J Orthop Surg. Res 2016;11:151
Go to original source...
Go to PubMed...
- Holmes M, Garver M, Albrecht L, Arbabi S, Pham TN. Comparison of two comorbidity scoring systems for older adults with traumatic injuries. J Am Coll. Surg 2014;219:631-637.
Go to original source...
Go to PubMed...
- Justiniano CF, Evans DC, Cook CH, Eiferman DS, Gerlach AT, Beery PR, 2nd, Lindsey DE, Saum GE, Murphy CV, Miller SF, Papadimos TJ, Steinberg SM, Stawicki SP. Comorbidity-polypharmacy score: a novel adjunct in post-emergency department trauma triage. J Surg Res. 2013;181:16-19.
Go to original source...
Go to PubMed...
- Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26:1039-1048.
Go to original source...
Go to PubMed...
- Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc. 2017;57:729-738.
Go to original source...
Go to PubMed...
- Mannucci PM, Nobili A, Investigators R. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014;9:723-734.
Go to original source...
Go to PubMed...
- Mubang RN, Stoltzfus JC, Cohen MS, Hoey BA, Stehly CD, Evans DC, Jones C, Papadimos TJ, Grell J, Hoff WS, Thomas P, Cipolla J, Stawicki SP. Comorbidity-Polypharmacy Score as Predictor of Outcomes in Older Trauma Patients: A Retrospective Validation Study. World J Surg. 2015;39:2068-2075.
Go to original source...
Go to PubMed...
- Panula J, Pihlajamaki H, Mattila VM, Jaatinen P, Vahlberg T, Aarnio P, Kivela SL. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord. 2011;12:105.
Go to original source...
Go to PubMed...
- Stewart NA, Chantrey J, Blankley SJ, Boulton C, Moran CG. Predictors of 5 year survival following hip fracture. Injury. 2011;42:1253-1256.
Go to original source...
Go to PubMed...
- Vestergaard P, Rejnmark L, Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int. 2007;18:1583-1593.
Go to original source...
Go to PubMed...
- Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study. Ann Pharmacother. 2016;50:89-95.
Go to original source...
Go to PubMed...